ACADIA Pharmaceuticals Company Insiders

ACAD Stock  USD 16.74  0.25  1.47%   
ACADIA Pharmaceuticals' insiders are aggressively selling. The analysis of the overall insider sentiment regarding ACADIA Pharmaceuticals suggests that all insiders are panicking. ACADIA Pharmaceuticals employs about 597 people. The company is managed by 43 executives with a total tenure of roughly 219 years, averaging almost 5.0 years of service per executive, having 13.88 employees per reported executive.
Leslie Iversen  Chairman
Independent Chairman of the Board
Stephen Davis  President
Executive Vice President CFO and Chief Business Officer

ACADIA Pharmaceuticals' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-04-08Brendan TeehanDisposed 2568 @ 17.87View
2024-03-27Stephen DavisDisposed 17714 @ 17.9View
2024-02-26Stephen DavisDisposed 5577 @ 24.67View
2024-01-08Stephen DavisDisposed 3732 @ 29.96View
2023-12-15James KiharaDisposed 2000 @ 28.3View
2023-11-20James KiharaDisposed 1985 @ 22.64View
2023-10-06Stephen DavisDisposed 51563 @ 21.96View
Monitoring ACADIA Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.

ACADIA Pharmaceuticals' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with ACADIA Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that ACADIA will maintain a workforce of about 600 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

ACADIA Pharmaceuticals' latest congressional trading

Congressional trading in companies like ACADIA Pharmaceuticals, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in ACADIA Pharmaceuticals by those in governmental positions are based on the same information available to the general public.
2022-06-16Representative Chris JacobsDisposed Under $15KVerify
2019-02-19Representative Gilbert CisnerosDisposed Under $15KVerify

ACADIA Pharmaceuticals Management Team Effectiveness

The company has return on total asset (ROA) of (0.0686) % which means that it has lost $0.0686 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1473) %, meaning that it created substantial loss on money invested by shareholders. ACADIA Pharmaceuticals' management efficiency ratios could be used to measure how well ACADIA Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of April 24, 2024, Return On Tangible Assets is expected to decline to -0.09. In addition to that, Return On Capital Employed is expected to decline to -0.16. At present, ACADIA Pharmaceuticals' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 41 M, whereas Non Currrent Assets Other are forecasted to decline to about 2.6 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 172 M, whereas Net Loss is forecasted to decline to (204.1 M).

ACADIA Pharmaceuticals Workforce Comparison

ACADIA Pharmaceuticals is rated fourth in number of employees category among related companies. The total workforce of Health Care industry is presently estimated at about 5,361. ACADIA Pharmaceuticals retains roughly 597 in number of employees claiming about 11% of equities under Health Care industry.

ACADIA Pharmaceuticals Profit Margins

The company has Profit Margin (PM) of (0.08) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.15 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.15.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.937
Significantly Down
Slightly volatile

ACADIA Pharmaceuticals Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ACADIA Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on ACADIA Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ACADIA Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
0.5
6
12
 65,797 
 99,445 
2024-03-01
1.1176
19
17
 765,674 
 67,483 
2023-12-01
0.6923
9
13
 168,342 
 241,351 
2023-09-01
0.1667
1
6
 100,000 
 283,602 
2023-06-01
1.7429
61
35
 1,951,536 
 238,828 
2023-03-01
0.65
13
20
 359,357 
 94,973 
2022-12-01
0.8333
5
6
 37,996 
 21,134 
2022-06-01
2.8333
34
12
 1,486,512 
 46,155 
2022-03-01
1.0667
16
15
 60,640 
 33,538 
2021-12-01
0.3125
5
16
 70,668 
 208,313 
2021-06-01
2.625
21
8
 182,704 
 45,656 
2021-03-01
1.3636
30
22
 725,687 
 239,251 
2020-12-01
0.5
5
10
 26,406 
 43,388 
2020-09-01
1.0
5
5
 37,952 
 54,500 
2020-06-01
0.75
30
40
 585,154 
 1,071,679 
2020-03-01
18.5
37
2
 1,468,274 
 20,000 
2019-12-01
0.4375
14
32
 491,572 
 972,270 
2019-09-01
0.8182
9
11
 1,620,967 
 121,579 
2019-06-01
3.0
15
5
 754,512 
 504,256 
2019-03-01
0.3333
1
3
 10,000 
 120,000 
2018-12-01
1.2727
14
11
 12,264,484 
 545,843 
2018-03-01
1.1429
8
7
 159,500 
 285,379 
2017-12-01
0.7
7
10
 1,505,468 
 1,600,366 
2017-09-01
1.625
13
8
 682,301 
 144,352 
2017-06-01
2.3333
7
3
 105,996 
 17,899 
2017-03-01
0.9375
15
16
 1,066,504 
 416,942 
2016-12-01
0.625
5
8
 44,135 
 74,135 
2016-09-01
2.25
9
4
 1,520,030 
 22,682 
2016-06-01
3.2
16
5
 562,573 
 145,086 
2016-03-01
12.5
25
2
 7,390,602 
 14,000 
2015-12-01
2.3333
7
3
 310,000 
 44,000 
2015-09-01
1.3333
4
3
 250,500 
 25,500 
2015-06-01
12.0
12
1
 140,627 
 7,627 
2015-03-01
1.1053
21
19
 833,975 
 305,170 
2014-12-01
0.65
13
20
 246,060 
 394,120 
2014-09-01
0.6316
12
19
 581,882 
 408,764 
2014-06-01
1.0417
25
24
 310,592 
 359,184 
2014-03-01
1.0588
18
17
 1,345,316 
 456,000 
2013-12-01
0.6667
14
21
 229,309 
 383,118 
2013-09-01
0.8214
23
28
 624,016 
 798,761 
2013-06-01
1.4
63
45
 5,622,301 
 1,306,412 
2013-03-01
0.7778
7
9
 55,500 
 40,500 
2012-12-01
0.5
3
6
 43,631 
 70,602 
2012-09-01
1.0
4
4
 59,166 
 59,166 
2010-03-01
0.5714
4
7
 900,000 
 110,000 
2009-09-01
1.0
2
2
 20,000 
 20,000 
2008-09-01
1.3333
4
3
 22,000 
 21,000 
2008-03-01
1.4167
17
12
 263,000 
 36,000 
2007-12-01
0.1818
4
22
 23,500 
 62,000 
2007-09-01
0.1212
4
33
 12,500 
 57,528 
2007-06-01
1.8571
13
7
 101,308 
 48,834 
2006-12-01
1.0
1
1
 3,000 
 3,000 
2006-09-01
0.6667
4
6
 130,916 
 37,000 
2006-06-01
6.5
13
2
 210,014 
 28,000 
2006-03-01
0.3636
4
11
 122,000 
 106,000 
2005-12-01
0.3333
2
6
 40,500 
 65,500 
2005-09-01
2.5
10
4
 163,900 
 44,000 
2004-06-01
0.7813
25
32
 7,625,385 
 3,789,195 

ACADIA Pharmaceuticals Notable Stakeholders

An ACADIA Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ACADIA Pharmaceuticals often face trade-offs trying to please all of them. ACADIA Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ACADIA Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Stephen JDCEO PresidentProfile
Leslie IversenIndependent Chairman of the BoardProfile
Stephen DavisExecutive Vice President CFO and Chief Business OfficerProfile
Michael YangExecutive Vice President Chief Commercial OfficerProfile
Austin KimExecutive Vice President General Counsel, SecretaryProfile
Todd YoungCFO, Executive Vice President Principal Financial Officer and Principal Accounting OfficerProfile
Srdjan StankovicExecutive Vice President Head - Research and DevelopmentProfile
Mark JohnsonVice President Investor RelationsProfile
Elena RidloffInterim CFO, Senior Vice PresidentProfile
Mark SchneyerExecutive CFOProfile
Glenn BaityExecutive VP, General Counsel and SecretaryProfile
Terrence MooreChief Commercial Officer and Executive VPProfile
Mary GrayIndependent DirectorProfile
Daniel SolandDirectorProfile
William WellsIndependent DirectorProfile
Edmund HarriganDirectorProfile
Lisa BarthelemyDirector of Investor RelationsProfile
Laura BregeIndependent DirectorProfile
James DalyDirectorProfile
Julian BakerDirectorProfile
Michael BorerIndependent DirectorProfile
Stephen BiggarIndependent DirectorProfile
Jim DalyDirectorProfile
Jennifer JDChief VPProfile
MPH MDGlobal SVPProfile
Parag PharmDSenior FranchiseProfile
Bob MischlerSenior StrategyProfile
Douglas MDExecutive DevelopmentProfile
James KiharaChief VPProfile
Rob AcklesSenior OfficerProfile
Julie FisherSenior StrategyProfile
Erika ZavodPlanning, StrategyProfile
Kevin OliverSenior OfficerProfile
Benir RuanoSenior OperationsProfile
Elizabeth ThompsonExecutive DevelopmentProfile
Albert KildaniSenior CommunicationsProfile
Eric MillerPrincipal Accounting Officer, ControllerProfile
Kimberly ManhardSenior ExecutionProfile
MSPH MDPresidentProfile
Holly ValdiviezSenior SalesProfile
Brendan TeehanCOO VPProfile
Sanjeev MDSenior DevelopmentProfile
Stephanie KimSenior AffairsProfile

About ACADIA Pharmaceuticals Management Performance

The success or failure of an entity such as ACADIA Pharmaceuticals often depends on how effective the management is. ACADIA Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ACADIA management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ACADIA management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.09)(0.09)
Return On Capital Employed(0.15)(0.16)
Return On Assets(0.08)(0.09)
Return On Equity(0.14)(0.15)
The data published in ACADIA Pharmaceuticals' official financial statements usually reflect ACADIA Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of ACADIA Pharmaceuticals. For example, before you start analyzing numbers published by ACADIA accountants, it's critical to develop an understanding of what ACADIA Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of ACADIA Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ACADIA Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in ACADIA Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ACADIA Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of ACADIA Pharmaceuticals' management manipulating its earnings.

ACADIA Pharmaceuticals Workforce Analysis

Traditionally, organizations such as ACADIA Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ACADIA Pharmaceuticals within its industry.

ACADIA Pharmaceuticals Manpower Efficiency

Return on ACADIA Pharmaceuticals Manpower

Revenue Per Employee1.2M
Revenue Per Executive16.9M
Net Loss Per Employee102.7K
Net Loss Per Executive1.4M
Working Capital Per Employee606.1K
Working Capital Per Executive8.4M
When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.
Note that the ACADIA Pharmaceuticals information on this page should be used as a complementary analysis to other ACADIA Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.

Complementary Tools for ACADIA Stock analysis

When running ACADIA Pharmaceuticals' price analysis, check to measure ACADIA Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ACADIA Pharmaceuticals is operating at the current time. Most of ACADIA Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ACADIA Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ACADIA Pharmaceuticals' price. Additionally, you may evaluate how the addition of ACADIA Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Is ACADIA Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.37)
Revenue Per Share
4.434
Quarterly Revenue Growth
0.693
Return On Assets
(0.07)
Return On Equity
(0.15)
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.